Episode 21: Cardiology and Boxing Promotion – A Sit-Down With Andrew Foy

Episode 21: Cardiology and Boxing Promotion – A Sit-Down With Andrew Foy

Andrew Foy, MD, cardiologist at Penn State University, joins the show to discuss publishing bias for medical research along with the psychological dilemma as a result of the pandemic of sacrificing personal liberties for the safety of others. The conversation pivots to Dr. Foy’s experience with boxing at a young age and how he eventually channeled that love into promoting the sport. How can promoting a boxing match be similar to planning a wedding? How can a full-time cardiologist balance his time while also promoting boxing matches? Dr. Foy provides a peek into the boxing world and the way COVID has impacted the sport in this riveting interview.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More